Dr. Oludamilola Abidemi Olajide, MD

Dr. Olajide practices at UNC Hospitals in Chapel Hill, North Carolina, part of University of North Carolina Health Care System.

Dr. Olajide's NPI, 1699730721, was assigned on April 20, 2006. Dr. Olajide holds North Carolina license 200400930.

Dr. Olajide's primary practice is UNC Hospitals, at 101 Manning Drive, Chapel Hill, NC 27514 in Orange County. The practice phone is (919) 966-4141.

Dr. Olajide's primary practice is UNC Hospitals in Chapel Hill, North Carolina, part of University of North Carolina Health Care System. Dr. Olajide is also affiliated with UNC Health Rex. The medical group on file is Legacy Healthcare Services. Dmand AI also links Dr. Olajide to 1 more therapy and rehab clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Olajide practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Olajide's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Olajide is licensed in North Carolina.

CMS data shows 283 Medicare services from Dr. Olajide across 4 procedure codes in 2024, all of them office visits, for 199 Medicare patients. Medicare paid $26,748 for them. Every service was in an office.

CMS counts 199 Medicare patients who saw Dr. Olajide in 2024. The largest group is 65 to 74, with 110 patients. 70% of them have high blood pressure, and 70% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Olajide's median patient age at 70, with 88% women.

In 2024, Dr. Olajide wrote 833 Medicare Part D claims for 202 patients. 82% of them were for generic drugs. CMS names the drug for 669 of them, across 23 drugs with 11 or more claims each, at $1,365,984 in total drug cost. In 2023, CMS named 924 claims across 21 drugs.

Dr. Olajide accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Olajide as offering telehealth.

Dmand AI links 9 papers to Dr. Olajide, published from 2011 to 2023. 2014 was the busiest year, with 2. The most frequent topics are Antineoplastic Agents, Hormonal, Breast Neoplasms and Cytochrome P-450 CYP2D6. Dr. Olajide has published most often in Oncologist. Dr. Olajide's most frequent co-authors are Steven William Corso, MD, James P. Evans, MD and Trevor Augustus Jolly, MD.

Dmand AI links Dr. Olajide to 1 clinical trial. Conditions studied include Triple Negative Breast Neoplasms and Breast Neoplasms.

CMS Open Payments shows 8 general payments to Dr. Olajide from 5 drug and device companies from 2016 to 2024. Education make up the largest share, 50% of the total. Incyte Corporation paid the most, $85.